Mr. Valazza's presentation, “Recent Advances in Oral Disintegrating Tablets, Oral Granules and Bi-Layer Tablets Technologies”, will take place on Sunday, July 31 from 8:30 - 9:30 AM as part of a releasing technology workshop (Maryland rooms 3 and 4).
This workshop will focus on new advancements in modified controlled release technologies, including novel OSDrC® OPTIDOSETM optimized dose delivery technology, controlled release and Lyopan® orally fast-dissolve technologies.
Optimized Products and Better Treatments:
OSDrC® OPTIDOSETM optimized dose delivery technology offers the broadest range of controlled release, combination (tablet-within-a-tablet) products, and orally disintegrating tablets to optimize dosing, therapeutic, and plasma release profiles to meet patient needs in a high quality, one step manufacturing process.
Click here to find out more about Catalent's OSDrC® OPTIDOSETM optimized dose delivery technology.
Lyopan® technology offers the potential for increasing the range of prescription and consumer drug products that can be formulated as a lyophilized fast- dissolve dosage form because it uses less water. This proprietary technology may be applicable to the formulation of higher doses of soluble drugs than is currently feasible and may enable incorporation of coated API for enhanced taste-masking and controlled release.
Click here to find out more about Catalent's Lyopan® fast-dissolve lyophilized tablet technology.
Throughout his 30 year career, Mr. Valazza has held various executive positions in product development and technical services with a focus on modified and controlled release solid dosage form applications. He is a recognized leader in the field of controlled release technology, having published articles in several scientific journals, and presented at numerous industry conferences. He currently leads Catalent's Controlled Release Technologies global team, and is based at their Somerset, NJ headquarters. Mr. Valazza is a registered pharmacist in New Jersey and Kentucky, with a Bachelor's degree in Pharmacy from Rutgers University, College of Pharmacy. He is a member of the Controlled Release Society (CRS) and American Association of Pharmaceutical Scientists (AAPS).
To arrange a follow-up interview with Mr. Valazza, please contact Patricia McGee at: [email protected].
Click here for more information or to register for the conference.
This workshop will focus on new advancements in modified controlled release technologies, including novel OSDrC® OPTIDOSETM optimized dose delivery technology, controlled release and Lyopan® orally fast-dissolve technologies.
Optimized Products and Better Treatments:
OSDrC® OPTIDOSETM optimized dose delivery technology offers the broadest range of controlled release, combination (tablet-within-a-tablet) products, and orally disintegrating tablets to optimize dosing, therapeutic, and plasma release profiles to meet patient needs in a high quality, one step manufacturing process.
Click here to find out more about Catalent's OSDrC® OPTIDOSETM optimized dose delivery technology.
Lyopan® technology offers the potential for increasing the range of prescription and consumer drug products that can be formulated as a lyophilized fast- dissolve dosage form because it uses less water. This proprietary technology may be applicable to the formulation of higher doses of soluble drugs than is currently feasible and may enable incorporation of coated API for enhanced taste-masking and controlled release.
Click here to find out more about Catalent's Lyopan® fast-dissolve lyophilized tablet technology.
Throughout his 30 year career, Mr. Valazza has held various executive positions in product development and technical services with a focus on modified and controlled release solid dosage form applications. He is a recognized leader in the field of controlled release technology, having published articles in several scientific journals, and presented at numerous industry conferences. He currently leads Catalent's Controlled Release Technologies global team, and is based at their Somerset, NJ headquarters. Mr. Valazza is a registered pharmacist in New Jersey and Kentucky, with a Bachelor's degree in Pharmacy from Rutgers University, College of Pharmacy. He is a member of the Controlled Release Society (CRS) and American Association of Pharmaceutical Scientists (AAPS).
To arrange a follow-up interview with Mr. Valazza, please contact Patricia McGee at: [email protected].
Click here for more information or to register for the conference.
Companies in this press-release
